ASP Isotopes has entered an agreement to supply Isotopia with enriched gadolinium-160 (Ga-160) for producing terbium-161 (Tb-161), a medical isotope used in targeted cancer radiotherapeutics.
The four-year supply agreement will commence in 2026 and is valued at $1 million per year. The Ga-160 supply will allow Isotopia to scale production and advance its Tb-161 drug candidates toward commercialization, with production taking place at the company’s facilities in Indianapolis, IN, according to the vendors.
Isotopia is collaborating with researchers to develop Tb-161-based therapies for prostate cancer, neuroendocrine tumors, and other malignancies, the companies noted in a release.
